Search research articles
Contact Us
Filters
Showing results (1-10 of 39) with videos related to
Page
of 4
Sort By:
Cancer Journal (Sudbury, Mass.)
|
December 24, 2003
The role of chemotherapy in the management of carcinoma of the cervix
Tate Thigpen
Clinical Obstetrics and Gynecology
|
February 21, 2012
A rational approach to the management of recurrent or persistent ovarian carcinoma
Tate Thigpen
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 28, 2003
Maybe more is better
Tate Thigpen
Seminars in Oncology
|
May 24, 2006
The role of gemcitabine in first-line treatment of advanced ovarian carcinoma
Tate Thigpen
Seminars in Oncology
|
February 13, 2002
The role of gemcitabine-based doublets in the management of ovarian carcinoma
Tate Thigpen
Cancer Investigation
|
December 3, 2004
First-line therapy for ovarian carcinoma: what's next?
Tate Thigpen
The New England Journal of Medicine
|
December 14, 2004
The if and when of surgical debulking for ovarian carcinoma
Tate Thigpen
Gynecologic Oncology
|
December 3, 2014
Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival
J Tate Thigpen
Lancet (London, England)
|
December 31, 2002
ICON3 and chemotherapy for ovarian cancer
Robert F Ozols, Maurie Markman, J Tate Thigpen
The American Surgeon
|
August 27, 2004
Management of women who present with T4 breast cancer
Galen V Poole, J Tate Thigpen, Ralph B Vance, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 39) with videos related to
Sort By:
Page
of 4
Cancer Journal (Sudbury, Mass.)
|
December 24, 2003
The role of chemotherapy in the management of carcinoma of the cervix
Tate Thigpen
Clinical Obstetrics and Gynecology
|
February 21, 2012
A rational approach to the management of recurrent or persistent ovarian carcinoma
Tate Thigpen
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 28, 2003
Maybe more is better
Tate Thigpen
Seminars in Oncology
|
May 24, 2006
The role of gemcitabine in first-line treatment of advanced ovarian carcinoma
Tate Thigpen
Seminars in Oncology
|
February 13, 2002
The role of gemcitabine-based doublets in the management of ovarian carcinoma
Tate Thigpen
Cancer Investigation
|
December 3, 2004
First-line therapy for ovarian carcinoma: what's next?
Tate Thigpen
The New England Journal of Medicine
|
December 14, 2004
The if and when of surgical debulking for ovarian carcinoma
Tate Thigpen
Gynecologic Oncology
|
December 3, 2014
Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival
J Tate Thigpen
Lancet (London, England)
|
December 31, 2002
ICON3 and chemotherapy for ovarian cancer
Robert F Ozols, Maurie Markman, J Tate Thigpen
The American Surgeon
|
August 27, 2004
Management of women who present with T4 breast cancer
Galen V Poole, J Tate Thigpen, Ralph B Vance, et al.
Page
of 4